The biopharmaceutical company paused the global clinical trial after a participant in the United Kingdom suffered an adverse reaction.
The New York Times reported the illness as transverse myelitis, an inflammation of the spinal cord that interrupts messages that nerves send throughout the body.
AstraZeneca has initiated a safety review and has not given a timeline for when the trial may resume.
More articles on spine:
The evolution of MIS SI joint: 6 key developments since CMS upped rates 27%
Losing its orthopedic provider to a competitor, New York system taps new partner
Orthopedic rankings, robotics & more: 6 key developments at Mayo Clinic during the pandemic
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
